国外投稿有关表格

国外投稿有关 表 关于同志近三年现实表现材料材料类招标技术评分表图表与交易pdf视力表打印pdf用图表说话 pdf 格 国外投稿有关表格 1．版权转让 协议 离婚协议模板下载合伙人协议 下载渠道分销协议免费下载敬业协议下载授课协议下载 Copyright Transfer Agreement 2．利益冲突声明 Conflict of Interest Disclosure Statement 3. 发表授权书 License to Publish 4. 权益双重性披露表 Duality of Interest Disclosure Form 5. 随机对照试验的统一报告格式 Consort Statement 1．版权转让协议 COPYRIGHT TRANSFER AGREEMENT Date: Contributor name: Contributor address: Manuscript number (if known): Re: Manuscript entitled (the “Contribution”) for publication in (the “Journal”) published by (“Wiley-Blackwell”). Dear Contributor(s): Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable Wiley-Blackwell to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement signed and returned as directed in the Journal’s instructions for authors as soon as possible. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement. CTA-A 25/05/2010 Changlin Mei Kidney institute of PLA, Department of Medicine, Changzheng Hospital, Shanghai, P.R.China DMRR-09-RES-243 Oxidized high-density lipoprotein enhances inflammatory activity in rat mesangial cells Diabetes/Metabolism Research and Reviews Wiley-Blackwell TRANSFER OF COPYRIGHT AGREEMENT Must be signed and returned to the production editor of the journal before the manuscript can be published The transfer of copyright from author to publisher must be clearly stated in writing to enable the publisher to assure maximum dissemination of the author’s work. Therefore, the following agreement, executed and signed by the author, is required with each manuscript submission. (If the article is a “work made for hire” it must be signed by the employer.) The article entitled __________________________________________________________________________________ __________________________________________________________ Manuscript number _____________________ is herewith submitted for publication in __________________________________________________________________ It has not been published before, and it is not under consideration for publication in any other journals. It contains no matter that is scandalous, obscene, libelous, or otherwise contrary to law. I have declared potential conflicts of interest and any relevant financial relationships I or my co-authors may have with third parties. When the article is accepted for publication, I, as the author (U.S. Government employees: see bottom of page), hereby agree to transfer to Informa Healthcare all rights, including those pertaining to electronic forms and transmissions, under existing copyright laws, except for the following, which the author(s) specifically retain(s): 1. The right to make further copies of all or part of the published article for my use in classroom teaching; 2. The right to reuse all or part of this material in a compilation of my own works or in a textbook of which I am the author; 3. The right to make copies of the published work for internal distribution within the institution that employs me. 4. The right to use or reuse all or part of the data and information used in compiling the manuscript as the author or their employer sees fit. For clarity, the author shall inform the copyright owner if they use any material directly extracted from the published article. 5. If I am in receipt of NIH funding, the right to deposit in PubMed Central the final version of the manuscript I submit for publication, with the restriction that a 12 month embargo on public access following publication is observed by PubMed Central. I agree that copies made under these circumstances will continue to carry the copyright notice that appeared in the original published work. I agree to inform my co-authors, if any, of the above terms. I certify that I have obtained written permission for the use of text, tables, and/or illustrations from any copyrighted source(s), and I agree to supply such written permission(s) to Informa Healthcare upon request. Signature and date _________________________________________________________________________________________________ Name and title ____________________________________________________________________________________________________ Institution or company (if appropriate) __________________________________________________________________________________ Government Copyright I certify that the above article has been written in the course of the author’s employment by the United States Government, so that it is not subject to U.S. copyright laws, or that it has been written in the course of the author’s employment by the United Kingdom Government (Crown Copyright). Signature and date _________________________________________________________________________________________________ Name and title ____________________________________________________________________________________________________ Note to U.S. Government Employees: If the above article was not prepared as part of the employee’s duties, it is not a U.S. Government work. If the above article was prepared jointly, and any co-author is not a U.S. Government employee, it is not a U.S. Government work. 2． 利益冲突声明 Conflict of Interest Disclosure Statement Each author is required to identify all relationships within the last 12 months that are relevant to the topic of the abstract and might be perceived as a real or potential conflict of interest. A relationship is "relevant" if the relationship or interest relates to the topic in terms of any of the following: the same or similar subject matter or topic; the same, similar or competing drug or device, product or service, intellectual property or asset; a drug or device company or its competitor; or has the reasonable potential to result in financial, professional or other personal gain or loss for you, members of your household or employer. • If you do not have any relationships to disclose, click the checkbox below. • If you do have relationships to disclose, click “Add” in the appropriate row and column to type in the name of the commercial interest. • Classify each relationship as either “Modest” or Significant.” A relationship is considered to be “Significant” if (a) the person receives $10,000 or more during any 12 month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “Modest” if it is less than “Significant” under the preceding definition. Click here for a description of financial disclosures. Only enter one relationship per text box. You may enter as many relationships as necessary by clicking “Add” each time. If there are no relationships to disclose, check here.     Modest Significant Employment 工作单位 Add Add Research Grant 研究经费 Add Add Other Research Support 其他研究赞助 Add Add Speakers Bureau 发言人办公室 Add Add Honoraria 酬金 Add Add Ownership Interest 研究成果归属 Add Add Consultant/Advisory Board 专家委员会 Add Add Other Add Add 3 . 发表授权书 LICENSE TO PUBLISH ________________________________________________________ Manuscript #: ..……………………………...………….. OBESITY (“the Journal”) Title of the contribution: ………………………………………………………………………………….…….…. (“the Contribution”) ……………………………………………………………………………………..….… Author(s): (names only) ………..………… …….……………… ….……………… ……….…….….. (“the Authors”) …………..……… …….……………… ….……………… …….…....……... To: The Obesity Society 1. In consideration of The Obesity Society agreeing to publish the Contribution the Authors grant to The Obesity Society for the full term of copyright in the Contribution and any extensions thereto, subject to clause 2 below, the exclusive license (a) to publish, reproduce, distribute, display and store the Contribution in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Contribution into other languages, create adaptations, summaries or extracts of the Contribution or other derivative works based on the Contribution and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts and derivative works and (c) to license others to do any or all of the above. 2. Ownership of copyright remains with the Authors, and provided that, when reproducing the Contribution or extracts from it, the Authors acknowledge first and reference publication in the Journal, the Authors retain the following non-exclusive rights: ​ a) To reproduce the Contribution in whole or in part in any printed volume (book or thesis) of which they are the author(s). ​ b) They and any academic institution where they work at the time may reproduce the Contribution for the purpose of course teaching. ​ c) To post a copy of the Contribution as accepted for publication after peer review (in Word or Tex format) on the Author’s own web site, or the Author’s institutional repository, or the Author’s funding body’s archive, six months after publication of the printed or online edition of the Journal, provided that they also link to the Journal article on NPG’s web site (e.g. through the DOI). ​ d) To reuse figures or tables created by them and contained in the Contribution in other works created by them. 3. The Authors warrant and represent that: ​ a) The Authors are the sole authors of and sole owners of the copyright in the Contribution. If the Contribution includes materials of others, the Authors have obtained the permission of the owners of the copyright in all such materials to enable them to grant the rights contained herein. Copies of all such permissions are attached to this license. ​ b) All of the facts contained in the Contribution are true and accurate. ​ c) The Author who has signed this Agreement has full right, power and authority to enter into this Agreement on behalf of all of the Authors. ​ d) Nothing in the Contribution is obscene, defamatory, libelous, violates any right of privacy or infringes any intellectual property rights (including without limitation copyright, patent or trademark) or any other human, personal or other rights of any person or entity or is otherwise unlawful. ​ e) Nothing in the Contribution infringes any duty of confidentiality which any of the Authors may owe to anyone else or violates any contract, express or implied, of any of the Authors, and all of the institutions in which work recorded in the Contribution was carried out have authorized publication of the Contribution. 4. The Authors authorize The Obesity Society to take such steps as it considers necessary at its own expense in the Authors’ name and on their behalf if it believes that a third party is infringing or is likely to infringe copyright in the Contribution. This Agreement and the rights and liabilities of the parties with respect to this Agreement and its subject matter, shall be governed by the laws of the State of New York, without reference to the principles of conflicts of laws thereof. Signed for and on behalf of the Authors: …………………………….……… Date: …..….……………… Please print name: …………………………………….………………….……………………………….………… Address: Please complete & sign this form, scan and upload to Manuscript Central as part of your manuscript submission. Alternatively, email to or send to Obesity, c/o The Obesity Society, 8630 Fenton Street, Suite 814, Silver Spring, MD 20910. Tel: +1 301 563 6526. Fax: +1 301 563 6595.hross@obesity.org. 4. 权益双重性披露表 OBESITY DUALITY OF INTEREST DISCLOSURE FORM Please complete & sign this form, scan and upload to Manuscript Central as part of your manuscript submission. Alternatively, email to hross@obesity.org or send to Obesity, c/o The Obesity Society, 8630 Fenton Street, Suite 814, Silver Spring, MD 20910. Tel: +1 301-563-6526. Fax: +1 301-563-6595. Manuscript #: ..……………………………...………….. Title: ………………………………………………………………………………….…….……. Please indicate below whether you have or have not had, in the previous 12 months, a relevant duality of interest with a company whose products or services are directly related to the subject matter of your manuscript. A relevant duality of interest includes employment, membership on the board of directors or any fiduciary relationship, membership on a scientific advisory panel or other standing scientific/medical committee, ownership of stock, receipt of honoraria or consulting fees, or receipt of financial support or grants for research. Company is defined as a for-profit concern engaged in the development, manufacture, or sale of pharmaceutical or biomedical devices or supplies. Any conflict of interest on the part of any of the authors must be revealed in the manuscript. Each author must check items and sign below. (This form may be photocopied if needed.) Yes No Yes No Yes No Yes No Employment ___ ___ ___ ___ ___ ___ ___ ___ Membership on an advisory panel, standing committee or board of directors ___ ___ ___ ___ ___ ___ ___ ___ Stock shareholder ___ ___ ___ ___ ___ ___ ___ ___ Honoraria or Consulting fees ___ ___ ___ ___ ___ ___ ___ ___ Grant/research support ___ ___ ___ ___ ___ ___ ___ ___ Author Name (type or print) _____________ _____________ _____________ _____________ Signature _____________ _____________ _____________ _____________ Date _____________ _____________ _____________ _____________ 5. 随机对照试验的统一报告格式 CONSORT Statement 2001 - Checklist Items to include when reporting a randomized trial PAPER SECTION And topic Item Descriptor Reported on Page # TITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., "random allocation", "randomized", or "randomly assigned"). INTRODUCTION Background 2 Scientific background and explanation of rationale. METHODS Participants 3 Eligibility criteria for participants and the settings and locations where the data were collected. Interventions 4 Precise details of the interventions intended for each group and how and when they were actually administered. Objectives 5 Specific objectives and hypotheses. Outcomes 6 Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors). Sample size 7 How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules. Randomization -- Sequence generation 8 Method used to generate the random allocation sequence, including details of any restrictions (e.g., blocking, stratification) Randomization -- Allocation concealment 9 Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned. Randomization -- Implementation 10 Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups. Blinding (masking) 11 Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. If done, how the success of blinding was evaluated. Statistical methods 12 Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses, such as subgroup analyses and adjusted analyses. RESULTS Participant flow 13 Flow of participants through each stage (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together with reasons. Recruitment 14 Dates defining the periods of recruitment and follow-up. Baseline data 15 Baseline demographic and clinical characteristics of each group. Numbers analyzed 16 Number of participants (denominator) in each group included in each analysis and whether the analysis was by "intention-to-treat". State the results in absolute numbers when feasible (e.g., 10/20, not 50%). Outcomes and estimation 17 For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision (e.g., 95% confidence interval). Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory. Adverse events 19 All important adverse events or side effects in each intervention group. DISCUSSION Interpretation 20 Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes. Generalizability 21 Generalizability (external validity) of the trial findings. Overall evidence 22 General interpretation of the results in the context of current evidence. www.consort-statement.org 6. A Cover Letter Sample Dear Editor: We would like to submit the enclosed manuscript entitled “Endothelial-specific intron-driven miR-126 is down regulated in human breast cancer and targets both VEGFA and PIK3R2”, which we wish could be considered for publication in….. MiRNAs are of great importance in regulation of many pathophysiologic processes, and the roles that miRNAs play in endothelial cells and tumors remain largely unknown. In this paper, we report that miR-126 and its host gene EGF-like domain 7 (egfl7) were strictly expressed in endothelial cells. We also demonstrated that miR-126 locating in an intron of egfl7 gene was processed from the excised intron without affecting splicing and expression of its host gene. Interestingly, miR-126 was down-regulated in breast tumors and vegfa and pik3r2 were both the targets of miR-126, indicating that miR-126 may play a role in tumor growth and endothelial homeostasis by regulating the VEGF/PI3K/AKT signaling pathway. On behalf of my co-authors, I hereby declare that this submission is our own work and to the best of our knowledge it contains no materials previously published or written by another person. Any contribution made to the research by others, with whom we have worked at the Second Military Medical University or elsewhere, is explicitly acknowledged in the thesis. All authors have read the manuscript and permitted to submit it to the journal. We suggest that…. as the editor. Due to a direct competition and conflict of interest, we request that…..not be considered as a reviewer. Thank you very much for your attention, and we look forward to hearing from you. Sincerely yours, Dr. Ni Zhu Department of Cardiology, Changhai Hospital, 168 Changhai Road, Shanghai 200433, PR China Tel and Fax: 8621-81873191 SCI -oncology journal -肿瘤学杂志小结 1. 肿瘤学报 Acta oncologica（Acta Oncol，ISSN：0284-186X ,IF：2004年为1.884），每年出版8期，为5个北欧肿瘤学学会会刊。由Taylor & Francis公司出版，该杂志网站提供免费的摘要电子版，全文电子版需付费订阅。杂志网址：http://www.tandf.co.uk/journals/titles/0284186x.asp。 主编：Bengt Glimelius（Uppsala, Sweden），编辑部地址及联系信息：Acta Oncologica, P.O. Box 3255, S-103 65, Stockholm, Sweden. Tel: +46 8 440 80 43, Fax: +46 8 440 80 50, E-mail:veronica.ahs@se.tandf.no。   2. 癌症研究进展 Advances in cancer research（Adv Cancer Res，ISSN：0065-230X ,IF：2004年为6.200），单本成卷,不定期但及时出版肿瘤学研究最新进展，由Elsevier公司出版发行，该杂志网站提供免费的摘要电子版， 网址： http://www.sciencedirect.com/science/bookseries/0065230X。主编：George Vande Woude, Director, Van Andel Research Institute, Grand Rapids, Michigan, U.S.A. 3. 美国临床肿瘤学杂志 American journal of clinical oncology（Am J Clin Oncol，ISSN：0277-3732 ,IF：2004年为1.703），双月刊，由Lippincott Williams & Wilkins公司出版, 该杂志网站提供免费的摘要电子版，全文电子版需付费订阅。杂志网址：http://www.amjclinicaloncology.com/pt/re/ajco/currenttoc. htm;jsessionid=DTjyctourH2aIVg7PcsWKwqSLNCEAnAe456NMdP3wd0O1O T55Jb3!1871300765!-949856144!9001!-1。 主编：David E. Wazer M.D.,Professor and Chairman，Departments of Radiation Oncology，Tufts University School of Medicine，Tufts New England Medical Center，Brown University School o